ArticleCancer medicine2025
Plasma-Based Genomic Features Influencing Outcomes of T790M-Positive Non-Small Cell Lung Cancer Receiving Osimertinib.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCirculating tumor DNA (ctDNA) provides a noninvasive method to clarify patients' genomic alterations. This study evaluated plasma-derived ctDNA before second-line osimertinib administration to explore the relationships between genomic alterations and clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC).
methodsWe included 64 advanced NSCLC patients with EGFR T790M receiving second-line osimertinib. Targeted DNA sequencing was conducted on plasma samples, and both clinical and genomic characteristics were assessed for the correlation with clinical outcomes.
resultsFemale patients showed longer progression-free survival (PFS) than male patients. Smokers exhibited shorter PFS and overall survival (OS) than nonsmokers. EGFR exon 19 deletion (E19Del) tended to have improved PFS compared with L858R. Plasma T790M abundance was not associated with the response to osimertinib, PFS, or OS. Patients with TP53 mutations experienced significantly worse PFS than wild-type ones. A significant PFS reduction was observed in patients with a blood tumor mutational burden (bTMB) ≥ 8, compared to those with a bTMB ⟨ 8 mut./Mb. The EGFR driver mutation type (E19Del versus L858R) and TP53 mutation status were independent factors influencing PFS by multivariate survival analysis. Furthermore, the combination of EGFR driver type and TP53 mutation status improved the predictive performance for clinical outcomes, including objective response rate (ORR) and PFS, but not OS.
conclusionThis study identified potential molecular features via ctDNA sequencing that were correlated to clinical outcomes in EGFR T790M-positive advanced NSCLC treated with second-line osimertinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.